Restoring Your
Muscle Strength

Biomaterials for orthopedic trauma and reconstructive surgery

Volumetric Muscle Loss

The damage caused by Volumetric Muscle Loss (VML) overwhelms the body's ability to regenerate muscle, making strength irrecoverable.

The Scale of the Problem

90% of muscle conditions in medically retired, battlefield-injured Service Members are due to VML
$380.9B in U.S. Health spending on musculoskeletal injuries (2017)
Over 250,000 traumatic muscle injuries a year
Over 80% of delayed amputations are caused by muscle trauma
Technology

MyoSponge

A muscle-regenerating implantable scaffold designed to mimic the Basal Lamina, which is the native support structure that allows muscle cells to Grow.

Patent
US 11744922 B2

How it works

01

Injury

Patient has VML after a car accident or gunshot injury. Surgeons remove the dead tissue.

02

Implantation

Surgeons implant MyoSponge to structurally support damaged muscle tissue from trauma.

03

Regeneration

Patient stem cells migrate into MyoSponge, multiply, and mature into new muscle fibers.

04

Resorption

MyoSponge gradually resorbs and is replaced by functional muscle tissue.

Clinical Applications

  • Compartment syndrome
  • Open fractures
  • Surgical tissue removal
  • High-impact trauma injuries

Patient Benefits

  • Increased muscle strength
  • Enhanced mobility
  • Improved well-being
  • First product indicated for traumatic muscle loss

The Science Behind GenAssist:

46%
Muscle Strength Improvement
Porcine model study(Unpublished)
$295K
NSF Phase I SBIR
National Science Foundation
Research

Validated in preclinical studies

GenAssist was awarded a $295,000 Phase I SBIR grant from the National Science Foundation to test MyoSponge in a porcine model of muscle trauma, demonstrating a 46% improvement in muscle strength.

Study Model
Large animal porcine model of volumetric muscle loss
Funding
National Science Foundation SBIR Phase I

Team

Joe leads fundraising and partnerships, raising over $500k for GenAssist. Across his ventures, he has secured over $1M, including investments from Baxter, Endeavor Health, and Hologic. With 3 publications, 2 patents, a clinical trial, and launch of a medical device, Joe confidently leads GenAssist towards commercial success.

Gabe co-invented MyoSponge and spearheads its development. As the CTO, he leads R&D for MyoSponge, oversees regulatory affairs, and manages GenAssist's finances. He acts as the principal investigator for our $295k NSF SBIR award and is a listed author on 10 publications, two patents, and a textbook chapter.

Dr. Garg is an Associate Professor of Biomedical Engineering at Saint Louis University and runs the Musculoskeletal Tissue Engineering Laboratory, where MyoSponge was invented. She provides scientific guidance, collaborates on grant applications, and conducts research on early-stage GenAssist products.

Deepanjali Patil, Ph.D., Senior Scientist Dr. Patil drives the optimization of MyoSponge and GenAssist’s manufacturing scale-up. She holds a Ph.D. in Organic Chemistry and brings over a decade of experience in biomaterials and drug delivery from roles at Transcera, Washington University, and George Mason. She has authored multiple publications and patents in tissue engineering.

Let's discuss your needs

We welcome your inquiries and will try to respond as soon as we can